AYTU BIOPHARMA, INC Quarterly Amortization of Intangible Assets in USD from Q3 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Aytu Biopharma, Inc quarterly/annual Amortization of Intangible Assets history and growth rate from Q3 2015 to Q2 2024.
  • Aytu Biopharma, Inc Amortization of Intangible Assets for the quarter ending June 30, 2024 was $1.3M, a 9.04% increase year-over-year.
  • Aytu Biopharma, Inc Amortization of Intangible Assets for the twelve months ending June 30, 2024 was $5.21M, a 8.86% increase year-over-year.
  • Aytu Biopharma, Inc annual Amortization of Intangible Assets for 2024 was $5.21M, a 8.86% increase from 2023.
  • Aytu Biopharma, Inc annual Amortization of Intangible Assets for 2023 was $4.79M, a 18.1% decline from 2022.
  • Aytu Biopharma, Inc annual Amortization of Intangible Assets for 2022 was $5.84M, a 2.75% decline from 2021.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $5.21M $1.3M +$108K +9.04% Apr 1, 2024 Jun 30, 2024 10-K 2024-09-26
Q1 2024 $5.1M $1.3M +$105K +8.77% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $5M $1.3M +$102K +8.51% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $4.9M $1.31M +$109K +9.11% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $4.79M $1.2M -$103K -7.94% Apr 1, 2023 Jun 30, 2023 10-K 2024-09-26
Q1 2023 $4.89M $1.2M -$306K -20.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $5.2M $1.2M -$307K -20.4% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 $5.5M $1.2M -$340K -22.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $5.84M $1.3M +$43K +3.43% Apr 1, 2022 Jun 30, 2022 10-K 2023-10-12
Q1 2022 $5.8M $1.5M -$81K -5.11% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $5.88M $1.51M -$79K -4.99% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-21
Q3 2021 $5.96M $1.54M -$48K -3.03% Jul 1, 2021 Sep 30, 2021 10-Q/A 2023-02-21
Q2 2021 $6.01M $1.26M -$306K -19.6% Apr 1, 2021 Jun 30, 2021 10-K 2022-09-27
Q1 2021 $6.32M $1.59M +$185K +13.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $6.13M $1.58M +$631K +66.1% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 $5.5M $1.59M +$1.01M +176% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $4.49M $1.56M +$986K +171% Apr 1, 2020 Jun 30, 2020 10-K 2021-09-28
Q1 2020 $3.5M $1.4M +$825K +143% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $2.68M $953K +$419K +78.5% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-11
Q3 2019 $2.26M $575K +$123K +27.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $2.14M $575K +$179K +45.1% Apr 1, 2019 Jun 30, 2019 10-K 2020-10-06
Q1 2019 $1.96M $575K +$188K +48.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $1.77M $534K +$150K +39.1% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
Q3 2018 $1.62M $452K +$66.1K +17.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $1.55M $396K -$1.28K -0.32% Apr 1, 2018 Jun 30, 2018 10-K 2019-09-26
Q1 2018 $1.55M $388K -$49.4K -11.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 $1.6M $384K -$53.2K -12.2% Oct 1, 2017 Dec 31, 2017 10-Q/A 2019-05-14
Q3 2017 $1.66M $386K -$51.2K -11.7% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $1.71M $398K +$17.7K +4.65% Apr 1, 2017 Jun 30, 2017 10-K 2018-09-06
Q1 2017 $1.69M $437K +$318K +268% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 $1.37M $437K +$329K +303% Oct 1, 2016 Dec 31, 2016 10-Q 2017-02-09
Q3 2016 $1.04M $437K +$380K +661% Jul 1, 2016 Sep 30, 2016 10-Q 2016-11-07
Q2 2016 $665K $380K Apr 1, 2016 Jun 30, 2016 10-K 2017-08-31
Q1 2016 $119K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q4 2015 $108K Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
Q3 2015 $57.4K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.